Purchase this article with an account.
B. Voykov, F. Ziemssen, M. Voelker, W. Inhoffen, K. U. Bartz-Schmidt, F. Gelisken; Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration: 12 Months Results. Invest. Ophthalmol. Vis. Sci. 2008;49(13):275.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the 12 months results of intravitreal bevacizumab treatment of neovascular age-related macular degeneration.
Retrospective, noncomparative, interventional case series of 125 consecutive patients (126 eyes) that underwent intravitreal bevacizumab treatment for subfoveal choroidal neovascularization by age-related macular degeneration was evaluated. Best corrected visual acuity (BCVA) was assessed at baseline and 12 month follow-up.
Mean BCVA was 20/81 at baseline and 20/111 at 12 month follow-up (p=0.003). In 70.6% (89/126) of the eyes, BCVA showed less than 3 lines worsening from baseline. Mean BCVA improved 1 or more lines in 33.9% (44/126) of the eyes and 3 or more lines in 13.5% (13/126) of the eyes. Six eyes developed retinal pigment epithelial tears. No endophthalmitis, retinal detachment or systemic side effects were seen.
Intravitreal bevacizumab injections can prevent vision loss in the majority of eyes with subfoveal neovascular age-related macular degeneration. One third of the eyes showed a vision improvement at 12 months. Larger controlled clinical trials are warranted to evaluate the effect of intravitreal bevacizumab therapy in neovascular age-related macular degeneration.
This PDF is available to Subscribers Only